Eli Lilly (LLY) Form 4: CEO David Ricks Reports 1,632-Share Purchase
Rhea-AI Filing Summary
David A. Ricks, President, Chair and CEO of Eli Lilly & Co., reported an open-market purchase of common stock. The Form 4 shows a purchase of 1,632 shares on 08/12/2025 at a weighted average price of $644.769 per share, with individual trade prices in the range $644.45 to $645.11. Following the reported transaction the filing shows 546,601.167 shares beneficially owned by the reporting person.
The filing also discloses indirect holdings: 54,117 shares in a 2022 GRAT, 300 shares by a Trust, 68,656 shares by a SLAT, and 7,295.84 shares in a 401(k). Footnotes state 16 shares from a family member's retirement account are included and that 5,340 shares were transferred to the reporting person on May 15, 2025 as an annuity payment under the GRAT.
Positive
- CEO purchase disclosed: David A. Ricks purchased 1,632 shares, showing an insider acquisition
- Clear pricing disclosure: weighted average purchase price provided as $644.769 with an explicit price range
- Detailed ownership breakdown: filing lists direct and multiple indirect holdings (GRAT, SLAT, Trust, 401(k)) and an annuity transfer of 5,340 shares
Negative
- None.
Insights
TL;DR: CEO David Ricks purchased 1,632 LLY shares at a weighted average of $644.769, increasing direct reported holdings to 546,601.167 shares.
The filing documents a modest open-market purchase by the company's CEO at a weighted average price of $644.769, with executed prices between $644.45 and $645.11. The disclosure quantifies both direct and detailed indirect holdings, including a 2022 GRAT and other trusts, and notes a prior annuity transfer of 5,340 shares. For investors, the filing provides clear, itemized ownership information; the purchase itself is relatively small relative to total reported beneficial ownership but is a direct acquisition by a senior executive.
TL;DR: Form 4 includes required disclosures, footnotes, and disclaimers showing detailed direct and indirect ownership reporting by the CEO.
The submission includes explicit footnotes explaining the weighted average price, inclusion of family retirement-account shares, an annuity transfer from the GRAT, and a standard disclaimer regarding pecuniary interest. The filing is signed by an authorized representative, indicating procedural compliance with Section 16 reporting. The disclosure of multiple indirect vehicles (GRAT, SLAT, Trust, 401(k)) provides transparency about how control and economic interests are allocated.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,632 | $644.769 | $1.05M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $644.45 to $645.11, inclusive. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Includes 16 shares previously held in a family member's retirement account. On May 15, 2025, 5,340 shares of Eli Lilly and Company common stock were transferred to the reporting person as an annuity payment in accordance with the terms of the Grantor Retained Annuity Trust, of which the reporting person is the trustee. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
